Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT

被引：35

作者：

Hoerner-Rieber, Juliane ^{[1
,2
,3
,4
]}

Bernhardt, Denise ^{[1
,2
,3
]}

Blanck, Oliver ^{[5
]}

Duma, Marciana ^{[6
]}

Eich, Hans Th ^{[7
]}

Gerum, Sabine ^{[8
]}

Gkika, Eleni ^{[9
]}

Hass, Peter ^{[10
]}

Henkenberens, Christoph ^{[11
]}

Herold, Hans-Ulrich ^{[12
]}

Hildebrandt, Guido ^{[13
]}

Imhoff, Detlef ^{[14
]}

Kahl, Henning ^{[15
]}

Janssen, Stefan ^{[16
,17
]}

Jurianz, Katrin ^{[18
]}

Krempien, Robert ^{[19
]}

Lautenschlaeger, Stefan Friedrich ^{[20
]}

Lohaus, Fabian ^{[21
,22
,23
,24
,25
,26
]}

Mueller, Arndt-Christian ^{[27
,28
]}

Petersen, Cordula ^{[29
]}

Sackerer, Irina ^{[30
]}

Scafa, Davide ^{[31
]}

Schrade, Elsge ^{[32
]}

Uhlmann, Lorenz ^{[33
]}

Wittig, Andrea ^{[34
]}

Guckenberger, Matthias ^{[35
]}

机构：

[1] Univ Hosp Heidelberg, Dept Radiat Oncol, INF 400, D-69120 Heidelberg, Germany

[2] Heidelberg Inst Radiat Oncol, Heidelberg, Germany

[3] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[4] German Canc Res Ctr, Clin Cooperat Unit Radiat Oncol, Heidelberg, Germany

[5] UKSH, Dept Radiat Oncol, Kiel, Germany

[6] Tech Univ Munich, Dept Radiat Oncol, Klinikum Rechts Isar, Munich, Germany

[7] Univ Munster, Dept Radiat Oncol, Munster, Germany

[8] LMU Ludwig Maximilians Univ Munich, Dept Radiat Oncol, Munich, Germany

[9] Univ Med Ctr Freiburg, Dept Radiat Oncol, Freiburg, Germany

[10] Univ Hosp Magdeburg, Dept Radiat Oncol, Magdeburg, Germany

[11] Med Sch Hannover, Dept Radiotherapy & Special Oncol, Hannover, Germany

[12] CyberKnife Ctr Erfurt, Erfurt, Germany

[13] Univ Rostock, Dept Radiat Oncol, Rostock, Germany

[14] Univ Hosp Frankfurt, Dept Radiat Oncol, Frankfurt, Germany

[15] Hosp Augsburg, Dept Radiat Oncol, Augsburg, Germany

[16] Med Practice Radiotherapy & Radiat Oncol, Hannover, Germany

[17] Univ Lubeck, Dept Radiat Oncol, Lubeck, Germany

[18] Gamma Knife Ctr Krefeld, Krefeld, Germany

[19] Helios Klinikum Berlin Buch, Dept Radiat Oncol, Berlin, Germany

[20] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Radiotherapy & Radiat Oncol, Marburg, Germany

[21] Tech Univ Dresden, Med Fac, Dept Radiat Oncol, Dresden, Germany

[22] Tech Univ Dresden, Univ Hosp CG Carus, Dresden, Germany

[23] German Canc Res Ctr, Heidelberg, Germany

[24] German Canc Consortium DKTK, Partner Site Dresden, Dresden, Germany

[25] Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany

[26] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany

[27] Eberhard Karls Univ Tuebingen, Univ Hosp, Dept Radiat Oncol, Tubingen, Germany

[28] Eberhard Karls Univ Tuebingen, Med Fac, Tubingen, Germany

[29] Univ Hosp Hamburg Eppendorf, Dept Radiat Oncol, Hamburg, Germany

[30] Radiat Oncol, Freising Weihenstephan, Germany

[31] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Radiat Oncol, Mannheim, Germany

[32] Hosp Heidenhe, Dept Radiat Oncol, Heidenheim, Germany

[33] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany

[34] Univ Hosp Jena, Dept Radiotherapy & Radiat Oncol, Jena, Germany

[35] Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland

来源：

CLINICAL LUNG CANCER | 2019年 / 20卷 / 06期

关键词：

Local therapy; Nonesmall-cell lung cancer (NSCLC); Oligometastases; Patterns of recurrence; Stereotactic body radiotherapy; CELL LUNG-CANCER; BODY RADIATION-THERAPY; LOCAL CONSOLIDATIVE THERAPY; PHASE-II; RADIOTHERAPY; MAINTENANCE; OUTCOMES; CHEMOTHERAPY; MULTICENTER; PROGRESSION;

D O I：

10.1016/j.cllc.2019.06.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This multicenter analysis included 301 patients with oligometastatic non-small-cell lung cancer treated with pulmonary stereotactic body radiotherapy for 336 lung metastases. In routine clinical practice, stereotactic body radiotherapy for pulmonary oligometastatic non-small-cell lung cancer achieved favorable local control and promising overall survival. The dominant failure pattern was distant with a continuously high risk of disease progression for many years. Prospective studies should therefore combine local therapy with novel systemic treatments. Introduction: This multicenter study aims to analyze outcome as well as early versus late patterns of recurrence following pulmonary stereotactic body radiotherapy (SBRT) for patients with oligometastatic non-small-cell lung cancer (NSCLC). Materials and Methods: This analysis included 301 patients with oligometastatic NSCLC treated with SBRT for 336 lung metastases. Although treatment of the primary tumor consisted of surgical resection, radiochemotherapy, and/or systemic therapy, pulmonary oligometastases were treated with SBRT. Results: The median follow-up time was 16.1 months, resulting in 2-year overall survival (OS), local control (LC), and distant control (DC) of 62.2%, 82.0%, and 45.2%, respectively. Multivariate analysis identified age (P = .019) and histologic subtype (P = .028), as well as number of metastatic organs (P < .001) as independent prognostic factors for OS. LC was superior for patients with favorable histologic subtype (P = .046) and SBRT with a higher biological effective dose at isocenter (P = .037), whereas DC was inferior for patients with metastases in multiple organs (P < .001) and female gender (P = .027). Early (within 24 months) local or distant progression was observed in 15.3% and 36.5% of the patients. After 24 months, the risk of late local failure was low, with 3- and 4-year local failure rates of only 4.0%, and 7.6%. In contrast, patients remained at a high risk of distant progression with 3- and 4-year failure rates of 13.3% and 24.1%, respectively, with no plateau observed. Conclusion: SBRT for pulmonary oligometastatic NSCLC resulted in favorable LC and promising OS. The dominant failure pattern is distant with a continuously high risk of disease progression for many years.

引用

页码：E667 / E677

页数：11

共 50 条

[21] Long-term follow-up in depressed patients treated with electroconvulsive therapy
Johanson, A
Gustafson, L
Risberg, J
Rosén, I
Sjöbeck, M
Silfverskiöld, P
JOURNAL OF ECT, 2005, 21 (04) : 214 - 220
[22] Long-term follow-up of patients with refractory GvHD treated with alefacept
Shapira, M. Y.
Dray, L.
Matusevich, A.
Resnick, I. B.
Stepansky, P.
Aker, M.
Or, R.
BONE MARROW TRANSPLANTATION, 2011, 46 : S65 - S66
[23] LONG-TERM FOLLOW-UP OF PARTIAL SEIZURE PATIENTS TREATED WITH VIGABATRIN
FRENCH, JA
BRODIE, MA
DOLLAR, L
DOW, MM
EPILEPSIA, 1995, 36 : D2 - D2
[24] Long-term follow-up of surgically treated gallbladder cancer patients
Puhalla, H
Wild, T
Bareck, E
Pokorny, H
Ploner, M
Soliman, T
Stremitzer, S
Depisch, D
Laengle, F
Gruenberger, T
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (08): : 857 - 863
[25] Long-term follow-up of achalasia patients treated with botulinum toxin
D'Onofrio, V
Miletto, P
Leandro, G
Iaquinto, G
DIGESTIVE AND LIVER DISEASE, 2002, 34 (02) : 105 - 110
[26] Long-term follow-up of achalasic patients treated with botulinum toxin
D'Onofrio, V
Annese, V
Miletto, P
Leandro, G
Marasco, A
Sodano, P
Iaquinto, G
DISEASES OF THE ESOPHAGUS, 2000, 13 (02) : 96 - 101
[27] Long-term follow-up of patients with neuromyelitis optica treated with rituximab
Kuempfel, T.
Havla, J.
Schuh, E.
Pellkofer, H.
Gerdes, L. A.
Meinl, I.
Hohlfeld, R.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 293 - 293
[28] Long-term evolution follow-up of patients treated with electroconvulsive therapy
Tajes, M. T. A.
Martinez, S. M. F.
Paramo, M. P. F.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S541 - S542
[29] LONG-TERM FOLLOW-UP OF MULTIPLE MYELOMA PATIENTS TREATED BY VELCADE
Michallet, M.
Sobh, M.
Le, Q. -H.
Barraco, F.
Nicolini, F. E.
Dumontet, C.
Chelghoum, Y.
Thomas, X.
Cannas, G.
Nicolas-Virelizier, E.
Plesa, N.
Ducastelle, S.
Troncy, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 618 - 619
[30] LONG-TERM FOLLOW-UP OF PATIENTS WITH IDIOPATHIC SCOLIOSIS NOT TREATED SURGICALLY
COLLIS, DK
PONSETI, IV
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1969, A 51 (03): : 425 - &

← 1 2 3 4 5 →